- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00538226
Evaluation of the Effect of the Flowaid Device in Increasing Local Circulation in the Leg
To Evaluate the Increase of Local Circulation in the Leg Using the Flowaid Device
This is an open label pilot study to evaluate the efficacy and the safety of the Flowaid device in increasing local circulation in the legs.
15 patients with a diagnosis of Peripheral Vascular Disease will be enrolled in this study. They will recieve tratment with the Flowaid device and monitored continuously by means of Laser Doppler Flowmetry as well as by tcPO2 and Digital Thermography. Subjective data will also be collected.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a 15 patient pilot study to evaluate efficacy and safety of use of the Flowaid device in increasing local circulation in the legs of patients with Peripheral Vascular Disease. Patients will be evaluated and scored prior to treatment and then treated with the Flowaid device for a period of two hours. During the treatment period patients will be continuously monitored by digital thermograph as well as by tcPO2 and Laser Doppler Flowmetry. Patients will also be monitored for a brief period immediately after cessation of treatment to evaluate continued effect of the device on local circulation in the leg.
The study will be individually controlled with each patients treated leg evaluated against the contralateral non- treated leg.
Subjective data including distance able to walk, pain and vibratory sensation threshold will also be collected and evaluated appropriately.
Type d'étude
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10035
- New York College of Podiatric Medicine
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Give appropriate written informed consent prior to participation in the study
- Have a current diagnosis of Type I or Type II Diabetes Mellitus
- Have an Ankle-Arm Index between 0.35 and 0.8 on the study limb
- Be in reasonable metabolic control, exhibited by HbA1C values of less than12% as observed by serum test results obtained within 3 months prior to the Screening Visit
- Subject and caregiver must be accessible for, and willing to comply with, the safety procedures and available for the 12 week Follow-Up Period
Exclusion Criteria:
- Clinical evidence of gangrene on any part of affected foot
- Active Charcot's foot on the study limb
- Scheduled to undergo vascular surgery, angioplasty, or thrombolysis within 30 days from the end of the study
- Malnourished as evidenced by a pre-albumin of < 11 mg/dL
- Pregnancy or lactating
- History of bleeding disorder
- Participation in another device study for the treatment of Peripheral Vascular Disease 30 days prior to Screening Visit
- Vascular procedures performed 30 days prior to Screening Visit
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Eileen Chusid, PHD, New York College of Podiatric Medicine
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- tali725
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .